Showing 6401-6410 of 8885 results for "".
- Melanoma Rates Drop Sharply Among Teens, Young Adultshttps://practicaldermatology.com/news/melanoma-rates-drop-sharply-among-teens-young-adults/2460217/Cases of melanoma among U.S. adolescents and young adults declined markedly from 2006 to 2015 - even as the skin cancer's incidence continued to increase among older adults and the general population during the span, new research in JAMA Dermatology shows. The finding,
- Allergan Pays Exicure $25M upfront in Collaboration Deal to Develop Hair Loss Treatmenthttps://practicaldermatology.com/news/allergan-pays-exicure-25m-upfront-in-collaboration-deal-to-develop-hair-loss-treatment/2460216/Allergan Pharmaceuticals International Limited has entered into a global collaboration agreement with Exicure to discover and develop novel treatments for hair loss disorders based on Exicure’s proprietary SNA technology. Allergan will receive exclusive access and options to licen
- Cassiopea Enrolls First Patient in Phase II Trial of Clascoterone Solution for the Treatment of Androgenetic Alopecia in Femaleshttps://practicaldermatology.com/news/cassiopea-enrolls-first-patient-in-phase-ii-trial-of-clascoterone-solution-for-the-treatment-of-androgenetic-alopecia-in-females/2460215/After receiving approval from the German Authority BfArM and the coordinating ethical committee, Cassiopea SpA is now enrolling the first patient in a Phase II trial investigating clascoterone solution for the treatment of androgenetic alopecia (AGA) in fema
- Post-Market Price Changes Alone Account for Most Recent Spending Growth for Biologics, and Rebates Have Little Impacthttps://practicaldermatology.com/news/post-market-price-changes-alone-account-for-most-recent-spending-growth-for-biologics-and-rebates-have-little-impact/2460214/Annual spending on biologics by U.S. public programs and beneficiaries nearly doubled from 2012 to 2016, according to research presented
- Live Zoster Vaccine Safe and Effective for Patients on TNF Blockershttps://practicaldermatology.com/news/live-zoster-vaccine-safe-and-effective-for-patients-on-tnf-blockers/2460213/The live zoster virus vaccine is safe for people who are currently receiving tumor necrosis factor inhibitor (TNFi) biologic therapies for various indications, according to
- Psoriasis Onset Determines if Psoriatic Arthritis Patients Develop Arthritis or Psoriasis Firsthttps://practicaldermatology.com/news/psoriasis-onset-determines-if-psoriatic-arthritis-patients-develop-arthritis-or-psoriasis-first/2460212/Age of psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis., finds a new study presented at the 2019 ACR/ARP Annual Meeting in Atlanta. Additionally, pustular psoriasis is associated with arthritis onset two years earlier than the in
- Researchers Elucidate Why Some Beta Blockers May Trigger or Exacerbate Psoriasishttps://practicaldermatology.com/news/researchers-elucidate-why-some-beta-blockers-may-trigger-or-exacerbate-psoriasis/2460211/Beta-blockers can trigger or exacerbate psoriasis, and now scientists at the University of Bonn and Freie Universität Berlin may know why. It appears that beta-blockers can interfere with the breakdown of defective cell components. In return, the cells release messengers that trigger immune-
- LEO Science & Tech Hub and Epicore Biosystems Advance AD Collabhttps://practicaldermatology.com/news/leo-science-tech-hub-and-epicore-biosystems-advance-ad-collab/2460208/LEO Science & Tech Hub, the Boston-based R&D innovation unit of LEO Pharma A/S, is starting the next phase of a research collaboration in atopic dermatitis (AD) with Epicore Biosystems, a wearable microfluidics and biosensor spinout from Northwestern University’s Center for Bio-Inte
- It's Official: Venus Concept Completes Merger with Restoration Roboticshttps://practicaldermatology.com/news/its-official-venus-concept-completes-merger-with-restoration-robotics/2460207/Venus Concept Inc. has completed its previously announced merger with Restoration Robotic, Inc., effective November 7, 2019. Following the completion of the merger, Venus Concept completed a $28 million equity financing by EW Healthcare Partners, HealthQuest Capital, SEDCO Capital
- Poll: People Who Developed AD Symptoms as Kids Experience More Severe Symptomshttps://practicaldermatology.com/news/poll-people-who-developed-ad-symptoms-as-kids-experience-more-severe-symptoms/2460206/Individuals who begin experiencing atopic dermatitis (AD) symptoms as children have vastly different patient journeys and experiences than those who began experiencing symptoms as adults, a new survey from Health Union suggests. Of the survey's 400 respondents, there was a nearly 50